REG - Futura Medical PLC - MED3000 commercial and US regulatory update

Futura MedicalAnnouncement

14/03/2023 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230314:nRSN8827Sa&default-theme=true

RNS Number : 8827S  Futura Medical PLC  14 March 2023

 

14 March 2023

 Futura Medical plc

("Futura" or the "Company")

 

Futura confirms initial launch of MED3000 under the Eroxon® brand

and continued progress towards regulatory approval in US

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, today
provides updates on commercial and US regulatory activities for MED3000,
Futura's novel, topical gel formulation for the treatment of erectile
dysfunction ("ED").

 

Eroxon launch

In May 2022, Futura announced an exclusive licensing agreement with Cooper
Consumer Health, a leading International independent self-care organisation
for the rights to commercialise MED3000 throughout the EEA, the United Kingdom
and Switzerland.

 

Futura is pleased to report that MED3000, under the brand name Eroxon™ is
now available online in Europe. On the 1st of April 2023 Eroxon will also be
available in retail pharmacies in Belgium supported by an advertising and
promotional campaign. Futura also confirms that further country launches,
supported by advertising and promotional campaigns, remain on track during the
coming months, as previously guided.

 

FDA Update

In October 2022 Futura filed an application for US marketing authorisation for
the MED3000 medical device via the De Novo regulatory pathway which is
undergoing detailed review. As a regular part of its review process, FDA have
asked some additional questions and requested some non-clinical confirmatory
data. The company expects to provide a full response to FDA's questions as
well as the requested confirmatory data no later than the end of March 2023,
to enable FDA to complete their review.

 

Based on FDA's published target review period guidelines to include time to
review the newly provided information, grant of the De Novo request is now
expected to be achieved in Q2 2023.

 

MED3000 is the Company's breakthrough, topical gel formulation for treatment
of erectile dysfunction ("ED").  It has the potential to become the first
globally available, clinically proven, over the counter ("OTC") treatment for
erectile dysfunction and has already been approved as the first pan-European
topical treatment for ED available without the need of a doctor's
prescription. The USA market is the largest ED market globally and the
Company's objective of US approval and OTC status for MED3000 continues to be
a top priority given its potential to be the first OTC clinically proven
treatment for ED in the region.

 

James Barder, Chief Executive Officer of Futura Medical said: "We are pleased
to confirm the online debut of Eroxon® with the product now available in
Europe.  This will be followed shortly by the first country-specific  retail
pharmacy launch supported by an advertising and promotional campaign.  We are
in constructive active dialogue with the FDA and believe we are making solid
progress in our efforts to be granted OTC marketing authorisation for MED3000
by the FDA which is now anticipated in Q2 2023."

 

ENDS

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

Liberum

Phil Walker / Richard Lindley / Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted an initial Phase 3 study using MED3000 in ED,
referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A
second confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED patients and
endpoints at 24 weeks, demonstrating that MED3000 presents an effective
clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for OTC classification.
 

 

Eroxon® is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile dysfunction
under the brand Eroxon® with a key claim of "Helps you get an erection within
10 minutes".  Eroxon® is the agreed brand name in certain regions such as
the EU whereas MED3000 continues to be the internal code name used by the
Company and also in reference to countries where regulatory approval or
commercial distribution agreements have not yet been achieved. www.eroxon.com
(http://www.eroxon.com)

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUSUWROKUOARR